[
  {
    "ts": null,
    "headline": "Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating",
    "summary": "Kenvue Inc. (NYSE:KVUE) is one of the most buzzing stocks to buy with huge upside potential. On October 24, Deutsche Bank lowered the firm’s price target on Kenvue to $18 from $20 and kept a Hold rating on the shares. Earlier on October 10, JPMorgan also lowered the firm’s price target on Kenvue to $21 […]",
    "url": "https://finnhub.io/api/news?id=a5bc0a74026d2bdfc9ea127fe5ae68dd764e9ca2a65115f09ef876f6ef7512d4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761753426,
      "headline": "Deutsche Bank Lowers Kenvue (KVUE) PT to $18, Keeps a Hold Rating",
      "id": 137259019,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue Inc. (NYSE:KVUE) is one of the most buzzing stocks to buy with huge upside potential. On October 24, Deutsche Bank lowered the firm’s price target on Kenvue to $18 from $20 and kept a Hold rating on the shares. Earlier on October 10, JPMorgan also lowered the firm’s price target on Kenvue to $21 […]",
      "url": "https://finnhub.io/api/news?id=a5bc0a74026d2bdfc9ea127fe5ae68dd764e9ca2a65115f09ef876f6ef7512d4"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue: Temporary Headwinds Don't Derail Its Consumer Health Dominance And 5.5% Dividend Yield",
    "summary": "Discover why Kenvue offers a 5.5% dividend yield and defensive value after a stock decline.",
    "url": "https://finnhub.io/api/news?id=1e5c742bd7f5af8ff7213b775870e3412aabdc41bae6a4c209e33a93be01cf73",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761748219,
      "headline": "Kenvue: Temporary Headwinds Don't Derail Its Consumer Health Dominance And 5.5% Dividend Yield",
      "id": 137256978,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2217234832/image_2217234832.jpg?io=getty-c-w1536",
      "related": "KVUE",
      "source": "SeekingAlpha",
      "summary": "Discover why Kenvue offers a 5.5% dividend yield and defensive value after a stock decline.",
      "url": "https://finnhub.io/api/news?id=1e5c742bd7f5af8ff7213b775870e3412aabdc41bae6a4c209e33a93be01cf73"
    }
  },
  {
    "ts": null,
    "headline": "Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls",
    "summary": "Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=a72c7cd0bda4d05565ed8145086c814dd07db0436548852a78c9cb03c33de656",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761744941,
      "headline": "Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls",
      "id": 137247899,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Skyworks upgraded, UnitedHealth downgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=a72c7cd0bda4d05565ed8145086c814dd07db0436548852a78c9cb03c33de656"
    }
  },
  {
    "ts": null,
    "headline": "Tylenol retail sales holding up despite Trump, lawsuits, and safety debate",
    "summary": "Across pharmacies, supermarkets and online marketplaces, Tylenol continues to sell steadily despite political commentary, litigation and a rolling safety debate.",
    "url": "https://finnhub.io/api/news?id=1ed68f7355c62e148ea4c2f99ac1e2b0721c9597baddd2c72af5415bf41076d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761741450,
      "headline": "Tylenol retail sales holding up despite Trump, lawsuits, and safety debate",
      "id": 137248330,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Across pharmacies, supermarkets and online marketplaces, Tylenol continues to sell steadily despite political commentary, litigation and a rolling safety debate.",
      "url": "https://finnhub.io/api/news?id=1ed68f7355c62e148ea4c2f99ac1e2b0721c9597baddd2c72af5415bf41076d6"
    }
  },
  {
    "ts": null,
    "headline": "Canaccord Genuity Downgrades Kenvue (KVUE)",
    "summary": "Canaccord Genuity Downgrades Kenvue (KVUE)",
    "url": "https://finnhub.io/api/news?id=ec17ed52614e1ad4dbe303e4a8bf3c2cadb814ddde14889768b6b84710875936",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739433,
      "headline": "Canaccord Genuity Downgrades Kenvue (KVUE)",
      "id": 137247449,
      "image": "",
      "related": "KVUE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=ec17ed52614e1ad4dbe303e4a8bf3c2cadb814ddde14889768b6b84710875936"
    }
  },
  {
    "ts": null,
    "headline": "Analysts Name 9 'Left Out' Stocks With Huge Upside Ahead",
    "summary": "When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.",
    "url": "https://finnhub.io/api/news?id=fa5bf95c2816f38c43cb3588cda5220e3fb8090fa86970edbd8ceeb4139b83be",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761739246,
      "headline": "Analysts Name 9 'Left Out' Stocks With Huge Upside Ahead",
      "id": 137248331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "When the S&P 500 is rallying to all-time highs, you have to wonder about the stocks getting left out. Turns out analysts see great promise.",
      "url": "https://finnhub.io/api/news?id=fa5bf95c2816f38c43cb3588cda5220e3fb8090fa86970edbd8ceeb4139b83be"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue Declares Quarterly Cash Dividend",
    "summary": "SUMMIT, N.J., October 29, 2025--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025.",
    "url": "https://finnhub.io/api/news?id=2d3a0804be05c3cb5bfd3849e9fd0fc78e038434c573d4f351f116e7e55611a9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761734700,
      "headline": "Kenvue Declares Quarterly Cash Dividend",
      "id": 137248334,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "SUMMIT, N.J., October 29, 2025--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock. The quarterly dividend is payable on November 26, 2025, to shareholders of record as of the close of business on November 12, 2025.",
      "url": "https://finnhub.io/api/news?id=2d3a0804be05c3cb5bfd3849e9fd0fc78e038434c573d4f351f116e7e55611a9"
    }
  },
  {
    "ts": null,
    "headline": "Kenvue (KVUE): Assessing Valuation as Legal Risks and Leadership Shifts Raise New Questions",
    "summary": "Kenvue (NYSE:KVUE) is in the spotlight following a new lawsuit from the Texas Attorney General that alleges Tylenol, one of its key brands, may be linked to autism. Ongoing legal questions, recent management changes, and updated medical guidance on Tylenol have created a cloud of uncertainty around the company’s stock this month. See our latest analysis for Kenvue. It’s been a turbulent stretch for Kenvue, with the share price dropping nearly 33% over the past 90 days and total shareholder...",
    "url": "https://finnhub.io/api/news?id=0b13077c1c902b20e6fa367d02a0bb358c58864e13fbf009223df2f6ad50b014",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761732534,
      "headline": "Kenvue (KVUE): Assessing Valuation as Legal Risks and Leadership Shifts Raise New Questions",
      "id": 137248338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Kenvue (NYSE:KVUE) is in the spotlight following a new lawsuit from the Texas Attorney General that alleges Tylenol, one of its key brands, may be linked to autism. Ongoing legal questions, recent management changes, and updated medical guidance on Tylenol have created a cloud of uncertainty around the company’s stock this month. See our latest analysis for Kenvue. It’s been a turbulent stretch for Kenvue, with the share price dropping nearly 33% over the past 90 days and total shareholder...",
      "url": "https://finnhub.io/api/news?id=0b13077c1c902b20e6fa367d02a0bb358c58864e13fbf009223df2f6ad50b014"
    }
  },
  {
    "ts": null,
    "headline": "Beauty product used by millions recalled for possible bacterial danger",
    "summary": "Roughly 1,300 cases of the recalled product were distributed across four states.There is a health risk: The bacterium Pluralibacter gergoviae can cause infections in vulnerable people. However, the Food and Drug Administration classifies the recall as Class II (low risk).Beauty-product recalls ...",
    "url": "https://finnhub.io/api/news?id=79e7491e98b34742b0814a08e20e0f307a7d622affd6786a647df67ea24ad51a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1761705180,
      "headline": "Beauty product used by millions recalled for possible bacterial danger",
      "id": 137244324,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "KVUE",
      "source": "Yahoo",
      "summary": "Roughly 1,300 cases of the recalled product were distributed across four states.There is a health risk: The bacterium Pluralibacter gergoviae can cause infections in vulnerable people. However, the Food and Drug Administration classifies the recall as Class II (low risk).Beauty-product recalls ...",
      "url": "https://finnhub.io/api/news?id=79e7491e98b34742b0814a08e20e0f307a7d622affd6786a647df67ea24ad51a"
    }
  }
]